GCIBelluscura enters joint venture to develop advanced oxygen therapy for wound care
Diabetic foot ulcers (DFUs) are a significant health challenge, frequently resulting in hospitalisation or lower extremity amputation for diabetics, and costing $79bn pa in the US alone.
Luckily, new technologies are being developed to help treat DFUs and other 'hard to heal' wounds, such as venous leg and pressure ulcers.
Enter () , a developer of best-in-class portable oxygen concentrators (POCs) used to treat respiratory conditions like COPD. Today, the firm said it had "entered into a product development joint venture with its research partner Separation Design Group and a major medical device company (MDC) to explore the use of oxygen-based wound care solutions".
Here will act as the device manufacturer, with the MDC funding product development, clinical trials, and distribution upon regulatory approval. An initial clinical study is scheduled to begin in early Q2'25 outside the US.
In terms of scale and potential upside, DFU and wound healing firm AOTI IPO'd on AIM in Jun'24 and is currently valued at c. £137m vs 's £17m. Plus, the wound care market is estimated to be worth around $22.5bn annually, and projected to achieve 5.9% CAGR between 2023-32 (Global Markets Insights).
CEO Bob Rauker commenting: "Our JV with Separation Design Group demonstrates the potential of leveraging our oxygen-based technology across broader therapeutic applications and healthcare challenges, such as addressing an unmet need in the hard-to-heal wounds market."
"Partnering with a globally recognized medical device company enables us to explore the development and commercialization of this innovative wound care solution by combining our oxygen enrichment technology and expertise with their resources and distribution capabilities."
Finally, in terms of the numbers, in Oct'24 house broker Dowgate Capital had a 35p/share target price, based on 's turnover climbing from $4.5m in 2024 to $20.0m next year and generating FY25 EBITDA of $0.8m.
As at 25 Oct’24, had cash reserves of $0.3m and $1.1m of receivables, excluding $9.6m of convertible loan notes - meaning that after securing a $4m working capital facility from Sallyport last month, further capital may be required in order to facilitate a full commercial launch of its groundbreaking DISCOV-R POC.
Follow News & Updates from Belluscura:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.